Peter Lio, MD: Innovations in JAK Inhibitors

April 12, 2022

Dr. Lio of Medical Dermatology Associates of Chicago reviews emerging innovations in JAK inhibitor therapies for atopic dermatitis. His discussion highlights several newly available treatments in this class and provides guidance for clinicians on incorporating these targeted therapies into patient care.

Topics Covered

Overview of JAK inhibitors in atopic dermatitis treatment
Clinical considerations for topical ruxolitinib
Oral JAK inhibitors including abrocitinib and upadacitinib
Practical guidance for selecting appropriate therapies for patients

Explore Related Resources

New Opportunities for JAK Inhibitors
Oral JAK Inhibitors—When and How?

MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS:

Andrew Blauvelt, MD, MBA: Reviewing Upadacitinib Data in Atopic Dermatitis

Dr. Blauvelt discusses the safety and efficacy of upadacitinib in patients with moderate-to-severe atopic dermatitis (AD). In terms of efficacy, he references the Heads Up

Zelma Chiesa Fuxench, MD, MSCE: Atopic Dermatitis Patient Selection and Expectations for Ruxolitinib

Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not responded adequately to topical corticosteroids

Andrew Mastro, MS, PA-C: Practical Prescribing and Patient Communication for Ruxolitinib in Atopic Dermatitis

Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients

Melinda Gooderham, MD, MSc: Best Practices for JAK Inhibition in Atopic Dermatitis

Dr. Gooderham discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK

Raj Chovatiya, MD, PhD, MSCI: Advancements in Topical Therapy for Atopic Dermatitis

Raj Chovatiya, MD, PhD, discusses advances in topical atopic dermatitis treatment, including ruxolitinib, rapid itch relief, and treatment of difficult areas.

David Seiter, FNP-C: Rapid Relief for Atopic Dermatitis Flares

David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after

Christopher Bunick, MD, PhD: Rapid Itch Relief with Upadacitinib vs. Dupilumab in Atopic Dermatitis

Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch

George Han, MD, PhD: Advancing Atopic Dermatitis Care: Early Use of Topical JAK Inhibitors

George Han, MD, PhD, discusses the evolving treatment strategies for patients with atopic dermatitis.

Kara Mudd DMSc, PA-C: Use of Ruxolitinib in Pediatric Patients with Atopic Dermatitis

Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion

Mona Shahriari, MD: Removal of Black Box Warnings Change Considerations for Hormonal Therapy in Atopic Dermatitis

Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment

Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis.

Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for

JCAD Archives